| Literature DB >> 32450842 |
Philipp A Loehrer1, Lars Timmermann2, Anika Pehl3, Corinna I Bien4, Andreas Pfestroff5, David J Pedrosa2.
Abstract
BACKGROUND: Cerebellar degeneration as a consequence of a malignancy is a rare condition most commonly related to the presence of anti-Yo, anti-Hu, and anti-Tr/DNER antibodies. In recent years, several reports have indicated Zinc-finger protein 4 (Zic4) antibodies being associated with paraneoplastic cerebellar degeneration (PCD) in patients with small cell lung carcinoma. However, the prevalence and the significance of Zic4-antibodies may be underestimated due to their co-occurrence with more frequent antibodies such as anti-Hu. A literature review of isolated Zic4 mediated paraneoplastic syndromes yielded 14 cases reporting mainly benign clinical courses when treated early. CASEEntities:
Keywords: Autoimmune Encephalitis; Case Report; Paraneoplastic Cerebellar Degeneration; Paraneoplastic Syndromes; Zic4
Year: 2020 PMID: 32450842 PMCID: PMC7249364 DOI: 10.1186/s12883-020-01788-z
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Antibodies assessed in this Case
| Immunoblot | Cell-based assays | Radioimmunoassay |
|---|---|---|
| Amphiphysin | GAD65 | VGCC |
| CV2/CRMP5 | NMDAR | |
| Ma2/Ta | GABABR | |
| Ri | IgLON5 | |
| Yo | AMPAR2 | |
| Hu | DPPX | |
| Recoverin | LGI1 | |
| Sox1 | CASPR2 | |
| Titin | Glycinereceptor | |
| Zic4 | mGluR5 | |
| DNER/Tr | mGluR1 |
Fig. 1Immunoblot and Immunofluorescence Test on Mouse Cerebellum. Demonstration of Zic4 antibodies in serum (the same results were obtained with cerebrospinal fluid, not shown). a On an immunoblot, 1:100 diluted patient serum produces on the right lane a band with Zic4 only (arrow and insert), not with any other antigen (Euroline DL 1111–1601-4 G, Euroimmun, Lübeck, Germany). The left lane was incubated with a control serum. b Incubation of patient serum, diluted 1:20, with unfixed mouse cerebellum (Euroimmun, Lübeck, Germany). Patient’s immunoglobulin G (IgG) binds in a Zic-4-typical pattern to the cerebellar granular cells (cf. Fig. 1 in Bataller et al., 2002 [5]). Bound antibodies are visualized by an anti-human-IgG antibody coupled to a red fluorochrome. Original magnification × 100. Bar: 100 μm. The area in the rectangle is shown in (C). c Original magnification × 400. Bar: 25 μm. Zic-4 IgG-antibodies bind to the nuclei of the granular layer and spare the nucleoli. Nuclear counterstaining with Hoechst 33342 1:10.000 in blue. ML = molecular layer; Pu = Purkinje cell layer; GL = granular layer; WM = white matter
Fig. 218F-FDG-PET Findings and SCLC Histology. a FDG-avid lesion in the right upper pulmonary lobe (red arrow) and non-specific uptake in cervical lymph nodes as a consequence of a mild inflammation. b Hematoxylin and eosin (HE) staining (magnification × 200), shows the tumor with typical basophil small cells with sparse cytoplasm and irregular nuclei. c Immunohistochemical (IH) staining for Synaptophysin (magnification × 200). Tumor tissue stains positive (brown), confirming neuroendocrine differentiation. d IH staining for Ki67 (magnification × 200) marks proliferating cells in a tumor. Proliferation rate was up to 70% in this case. e IH staining for TTF-1 (magnification × 200), shows the typical nuclear staining of cells of pulmonary origin
Summary of Case Reports of isolated Zic4-Antibodies
| Author | Age/Sex | Associated Tumor | Primary syndrome at Diagnosis | Symptoms | Treatment | Treatment response |
|---|---|---|---|---|---|---|
| Current Study | 67/F | SCLC | Brainstem, PCD | Opsoclonus-Myoclonus Syndrome, Dysautonomia | Methylprednisolone, Plasmapheresis, IVIG, Lobectomy, Cyclophosphamide | none |
| Salazar et al. 2018 [ | 70/M | None, sCJD | Brainstem, PCD | Dementia, Ataxia, Myoclonus, Dysautonomia | Methylprednisolone | none |
| Eye et al. 2018 [ | 94/F | DLBCL, SMM | PCD | Downbeat Nystagmus, alternating Skew Deviation, Gait Ataxia | Chemotherapy, Rituximab | Improvement but persisting symptoms |
| Aydin et al. 2018 [ | 40/F | Ductal breast cancer | SSN | Pain, Asymmetric Numbness | n/a | Improvement but persisting symptoms |
| Kerasnoudis et al. 2011 [ | 60/F | Ovarian adenocarcinoma | PCD | Progressive Gait Ataxia, Dysarthria | Methylprednisolone, Ovariectomy, Chemotherapy | Complete clinical remission |
| Sabater et al. 2008 [ | n/a | SCLC | PCD | n/a | n/a | n/a |
| Bataller et al. 2004 [ | 67a/ 8: M, 1: F | 8: SCLC 1: no tumor | 7: PCD 1: PCD + LE 1: LEMS | Cerebellar Ataxia Cerebellar Ataxia, Cognitive Dysfunction Myasthenia | n/a | n/a |
amedian age